Why the Price Target for Pacific Biosciences of California Matters Now Pacific Biosciences of California is back in focus as ...

What Is Actually Changing In PacBio’s Fair Value Story? Analysts have lifted their fair value estimate for Pacific ...

PacBio (NASDAQ: PACB), developer of the world's most advanced sequencing technologies, today announced plans to pursue a strategic collaboration with the n-Lorem Foundation and EspeRare that we ...

Pacific Biosciences of California, Inc. PACB, popularly known as PacBio, announced a new community-developed method, CiFi, ...

Pacific Biosciences of California (PACB) ended the recent trading session at $2.58, demonstrating a -3.37% change from the ...

(RTTNews) - PacBio (PACB), a developer of highly accurate sequencing solutions, is slated to participate in several upcoming investor conferences this month, underscoring its visibility within the ...

Now that Pacific Biosciences has broken through the $1 level that avoids Nasdaq delisting for now, we can focus on what might be ahead: the near-term path to cash flow breakeven. PacBio’s biggest ...

MENLO PARK, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced preliminary unaudited revenue for the ...

Pacific Biosciences of California, Inc. PACB, popularly known as PacBio, delivered an adjusted loss per share of 13 cents in second-quarter 2025, narrower than the year-ago adjusted loss of 20 cents ...

PacBio reports that through its partnership with China-headquartered Berry Genomics, the Sequel II CNDx system has received Class III Medical Device Registration approval from the National Medical ...